163 related articles for article (PubMed ID: 15003635)
1. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers.
Bruge J; Bouveret-Le Cam N; Danve B; Rougon G; Schulz D
Vaccine; 2004 Mar; 22(9-10):1087-96. PubMed ID: 15003635
[TBL] [Abstract][Full Text] [Related]
2. Activity and cross-reactivity of antibodies induced in mice by immunization with a group B meningococcal conjugate.
Coquillat D; Bruge J; Danve B; Latour M; Hurpin C; Schulz D; Durbec P; Rougon G
Infect Immun; 2001 Nov; 69(11):7130-9. PubMed ID: 11598089
[TBL] [Abstract][Full Text] [Related]
3. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine.
Jennings HJ; Roy R; Gamian A
J Immunol; 1986 Sep; 137(5):1708-13. PubMed ID: 3091688
[TBL] [Abstract][Full Text] [Related]
4. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
[TBL] [Abstract][Full Text] [Related]
5. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
[TBL] [Abstract][Full Text] [Related]
6. Safety and preliminary immunogenicity of MenC/P64k, a meningococcal serogroup C conjugate vaccine with a new recombinant carrier.
Pérez AE; Dickinson FO; Banderas F; Serrano T; Llanes R; Guzmán D; Díaz P; Alvarez A; Guirola M; Caballero E; Canaan-Haden L; Guillén G
FEMS Immunol Med Microbiol; 2006 Apr; 46(3):386-92. PubMed ID: 16553812
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
[TBL] [Abstract][Full Text] [Related]
8. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines.
Toropainen M; Saarinen L; Wedege E; Bolstad K; Mäkelä PH; Käyhty H
Vaccine; 2005 Sep; 23(40):4821-33. PubMed ID: 15970361
[TBL] [Abstract][Full Text] [Related]
9. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults.
Campbell JD; Edelman R; King JC; Papa T; Ryall R; Rennels MB
J Infect Dis; 2002 Dec; 186(12):1848-51. PubMed ID: 12447774
[TBL] [Abstract][Full Text] [Related]
10. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
[TBL] [Abstract][Full Text] [Related]
11. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.
Keyserling H; Papa T; Koranyi K; Ryall R; Bassily E; Bybel MJ; Sullivan K; Gilmet G; Reinhardt A
Arch Pediatr Adolesc Med; 2005 Oct; 159(10):907-13. PubMed ID: 16203934
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
[TBL] [Abstract][Full Text] [Related]
13. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults.
Kshirsagar N; Mur N; Thatte U; Gogtay N; Viviani S; Préziosi MP; Elie C; Findlow H; Carlone G; Borrow R; Parulekar V; Plikaytis B; Kulkarni P; Imbault N; LaForce FM
Vaccine; 2007 Sep; 25 Suppl 1():A101-7. PubMed ID: 17532101
[TBL] [Abstract][Full Text] [Related]
14. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
[TBL] [Abstract][Full Text] [Related]
15. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man.
Zollinger WD; Mandrell RE; Griffiss JM; Altieri P; Berman S
J Clin Invest; 1979 May; 63(5):836-48. PubMed ID: 109466
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.
Ostergaard L; Lebacq E; Poolman J; Maechler G; Boutriau D
Vaccine; 2009 Jan; 27(1):161-8. PubMed ID: 18834910
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
[TBL] [Abstract][Full Text] [Related]
18. A conjugate vaccine composed of a heat shock protein 60 T-cell epitope peptide (p458) and Neisseria meningitidis type B capsular polysaccharide.
Amir-Kroll H; Riveron L; Sarmiento ME; Sierra G; Acosta A; Cohen IR
Vaccine; 2006 Oct; 24(42-43):6555-63. PubMed ID: 16843573
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
20. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
